Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion DOI
Diana Gumber, Leo D. Wang

EBioMedicine, Journal Year: 2022, Volume and Issue: 77, P. 103941 - 103941

Published: March 1, 2022

Language: Английский

Pan-cancer single-cell landscape of tumor-infiltrating T cells DOI
Liangtao Zheng, Shishang Qin, Wen Si

et al.

Science, Journal Year: 2021, Volume and Issue: 374(6574)

Published: Dec. 16, 2021

T cells play a central role in cancer immunotherapy, but we lack systematic comparison of the heterogeneity and dynamics tumor-infiltrating across types. We built single-cell RNA-sequencing pan-cancer atlas for 316 donors 21 types revealed distinct cell composition patterns. found multiple state-transition paths exhaustion CD8+ preference those among different tumor Certain populations showed specific correlation with patient properties such as mutation burden, shedding light on possible determinants microenvironment. compositions within tumors alone could classify patients into groups clinical trait specificity, providing new insights immunity precision immunotherapy targeting cells.

Language: Английский

Citations

860

Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms DOI Creative Commons
Jean‐Christophe Beltra, Sasikanth Manne, Mohamed S. Abdel-Hakeem

et al.

Immunity, Journal Year: 2020, Volume and Issue: 52(5), P. 825 - 841.e8

Published: May 1, 2020

Language: Английский

Citations

738

Acquired Resistance to Immune Checkpoint Inhibitors DOI Creative Commons
Adam J. Schoenfeld, Matthew D. Hellmann

Cancer Cell, Journal Year: 2020, Volume and Issue: 37(4), P. 443 - 455

Published: April 1, 2020

Language: Английский

Citations

665

The Next Decade of Immune Checkpoint Therapy DOI Open Access
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan

et al.

Cancer Discovery, Journal Year: 2021, Volume and Issue: 11(4), P. 838 - 857

Published: April 1, 2021

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve overall survival. However, only subsets of patients with specific tumor types respond to ICT. Thus, significant challenges remain, including understanding pathways resistance, optimizing patient selection, improving management immune-related adverse events, identifying rational therapeutic combinations. These will need a focused approach encompassing both basic research, the integration reverse translational studies. This integrated lead identification potential targets for subsequent trials, which guide decisions as we develop novel combination strategies maximize efficacy minimize toxicities patients. SIGNIFICANCE: ICTs induce antitumor cancer. Recent evidence suggests that combinatorial response by overcoming primary adaptive resistance mechanisms, although these may carry an increased risk immune-mediated toxicities. review surveys current mechanisms active areas investigation, proposes path forward minimizing through better selection

Language: Английский

Citations

545

Targeting the epigenetic regulation of antitumour immunity DOI
Simon J. Hogg, Paul A. Beavis, Mark A. Dawson

et al.

Nature Reviews Drug Discovery, Journal Year: 2020, Volume and Issue: 19(11), P. 776 - 800

Published: Sept. 14, 2020

Language: Английский

Citations

454

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling DOI
Evan W. Weber, Kevin R. Parker, Elena Sotillo

et al.

Science, Journal Year: 2021, Volume and Issue: 372(6537)

Published: April 1, 2021

CAR-T cells rest to get back in the race Chimeric antigen receptor (CAR)–T cells, which are engineered target specific tumor antigens, increasingly used as an immunotherapy. have shown promising results patients, particularly hematologic cancers, but their anticancer activity can be limited by onset of exhaustion and loss effectiveness. Weber et al. characterized phenotypic epigenomic changes associated with cell caused continuous beneficial effects transient periods (see Perspective Mamonkin Brenner). The authors tested different approaches for providing these periods, such using drug dasatinib temporarily suppress T activity, helped prevent improved antitumor mouse models. Science , this issue p. eaba1786 ; see also 34

Language: Английский

Citations

453

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy DOI Creative Commons
Ri‐Yao Yang, Linlin Sun, Ching-Fei Li

et al.

Nature Communications, Journal Year: 2021, Volume and Issue: 12(1)

Published: Feb. 5, 2021

The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted differentiation, recent evidence suggests that their crosstalk regulates exhaustion immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show contributes to persistence of

Language: Английский

Citations

423

Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging DOI Creative Commons
Denis A. Mogilenko, Oleg Shpynov,

Prabhakar S. Andhey

et al.

Immunity, Journal Year: 2020, Volume and Issue: 54(1), P. 99 - 115.e12

Published: Dec. 2, 2020

Language: Английский

Citations

407

Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion DOI
Yi-Ru Yu, Hana Imrichová,

Haiping Wang

et al.

Nature Immunology, Journal Year: 2020, Volume and Issue: 21(12), P. 1540 - 1551

Published: Oct. 5, 2020

Language: Английский

Citations

391

Metabolic barriers to cancer immunotherapy DOI
Kristin DePeaux, Greg M. Delgoffe

Nature reviews. Immunology, Journal Year: 2021, Volume and Issue: 21(12), P. 785 - 797

Published: April 29, 2021

Language: Английский

Citations

384